Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

EPS and iPS Cells in Disease Research

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Hypoxia-Induced Epas1-Myl9/12 Axis Shapes the Pathology of Pulmonary Hypertension.

Circulation research·2026

Same author

Reduced platelet formation associated with serine metabolic dysregulation in integrin αIIbβ3-deficient megakaryocytes.

Blood·2026

Same author

Induced pluripotent stem cell-derived platelets kill multidrug-resistant <i>Staphylococcus aureus</i> via Toll-like receptor 2-MyD88 signaling and immunoglobulin G/FcγRIIA engagement.

Research and practice in thrombosis and haemostasis·2026

Same author

Chromatin accessibility in stem cells unveils progressive transcriptional alterations in myelodysplastic syndrome.

Nature communications·2025

Same author

Aging-dependent reduction of KAT7/HBO1 activity impairs imMKCL-based platelet production by promoting immune properties.

Stem cell reports·2025

Same author

Bone morphogenetic protein-2-independent bone formation by human iPSC-derived megakaryocytes and platelets.

Bone·2025

Search research articles

Related Experiment Video

Updated: Dec 30, 2025

Scalable 96-well Plate Based iPSC Culture and Production Using a Robotic Liquid Handling System

Scalable 96-well Plate Based iPSC Culture and Production Using a Robotic Liquid Handling System

Published on: May 14, 2015

Platelets using iPS cell technology; large scale manufacturing.

¹Department of Regenerative Medicine, Graduate School of Medicine Chiba University, Chiba; Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Journal of Stem Cells & Regenerative Medicine

|January 28, 2020

Summary

Induced pluripotent stem cell-derived platelets (iPS-platelets) offer a promising alternative to blood donations, addressing shortages and transfusion issues. Large-scale bioreactor production yields functional iPS-platelets comparable to donor platelets.

More Related Videos

Efficient iPS Cell Generation from Blood Using Episomes and HDAC Inhibitors

Efficient iPS Cell Generation from Blood Using Episomes and HDAC Inhibitors

Published on: October 28, 2014

Production of Autologous Platelet-Rich Plasma for Boosting In Vitro Human Fibroblast Expansion

Production of Autologous Platelet-Rich Plasma for Boosting In Vitro Human Fibroblast Expansion

Published on: February 24, 2021

Related Experiment Videos

Last Updated: Dec 30, 2025

Scalable 96-well Plate Based iPSC Culture and Production Using a Robotic Liquid Handling System

Scalable 96-well Plate Based iPSC Culture and Production Using a Robotic Liquid Handling System

Published on: May 14, 2015

Efficient iPS Cell Generation from Blood Using Episomes and HDAC Inhibitors

Efficient iPS Cell Generation from Blood Using Episomes and HDAC Inhibitors

Published on: October 28, 2014

Production of Autologous Platelet-Rich Plasma for Boosting In Vitro Human Fibroblast Expansion

Production of Autologous Platelet-Rich Plasma for Boosting In Vitro Human Fibroblast Expansion

Published on: February 24, 2021

Area of Science:

Biotechnology
Hematology
Regenerative Medicine

Background:

Current platelet transfusion relies on voluntary donors, facing shortages due to aging populations and younger donor decline.
Platelet transfusion refractoriness, caused by alloimmune responses, limits treatment options for certain patients.
Induced pluripotent stem cells (iPSCs) offer a potential source for generating platelet-like particles (iPS-platelets).

Purpose of the Study:

To develop an alternative platelet source using iPSCs to address donor shortages and transfusion refractoriness.
To establish expandable megakaryocyte cell lines for manufacturing cGMP-grade platelets.
To scale up iPS-platelet production using novel bioreactor technology.

Main Methods:

Established expandable megakaryocyte lines from iPSCs.
Scaled up iPS-platelet production in an 8L bioreactor with optimized physical parameters.
Conducted in vitro and in vivo evaluations to assess iPS-platelet functionality and safety.

Main Results:

Successfully produced over 100 billion iPS-platelets in a single bioreactor run, approaching the quantity of one unit of platelet concentrate.
Demonstrated that iPS-platelets exhibit comparable functionality to donor-derived platelets in both in vitro and in vivo assessments.
Developed a scalable manufacturing process for iPS-platelets.

Conclusions:

iPS-platelets represent a viable alternative to donor-derived platelets, potentially overcoming supply limitations and transfusion complications.
The developed bioreactor system enables large-scale production of functional iPS-platelets.
Future work includes developing universal HLA class-I knockout platelets for broader clinical application and industrial production.